Silence Therapeutics plc

NASDAQ:SLN

Biotechnology

Healthcare
$19.82 +2.81%

+$0.19 today

Market cap
$936.18M
Beta
1.48
P/E (TTM)
-3.9
EPS (TTM)
-$1.80
52W Low $4.19High $8.40

Volume 1.47M

Average 0.31M

Income Statement

Follow revenue through to earnings.

Revenue

$559,000.00

FY 2025 · Annual

-98.7% YoY

Operating Income

-$89.75M

FY 2025 · Annual

Net Income

-$88.61M

FY 2025 · Annual

Income Statement

Mixed currencies
Metric
FY2021
Dec 2021 · GBP
FY2022
Dec 2022 · GBP
FY2023
Dec 2023 · GBP
FY2024
Dec 2024 · GBP
FY2025
Dec 2025 · USD
Revenue12.42M17.65M25.38M43.26M559K
Cost of Revenue7.46M10.97M10.32M11.81M215K
Gross Profit4.96M6.68M15.06M31.45M344K
Gross Margin39.9%37.8%59.3%72.7%61.5%
Research & Development30.77M35.5M44.03M67.88M67.75M
Selling, General & Admin20.01M20.94M20.64M26.88M22.34M
Operating Expenses50.77M56.44M64.66M94.77M90.1M
Depreciation & Amortization427K485.86K498K593K555K
EBITDA(45.42M)(39.94M)(49.78M)(48.99M)(88.05M)
EBITDA Margin-365.9%-226.2%-196.2%-113.2%-15750.6%
Operating Income(45.81M)(49.76M)(49.6M)(63.32M)(89.75M)
Operating Margin-369.0%-281.9%-195.5%-146.4%-16056.0%
Interest Income10K226K1.45M4.47M3.48M
Interest Expense8K47K34K00
Other Income / Expenses(42K)9.29M(706K)18.86M1.15M
Income Before Tax(45.86M)(40.47M)(50.31M)(44.46M)(88.6M)
Pre-Tax Margin-369.4%-229.3%-198.3%-102.8%-15849.9%
Income Tax Expense(6.45M)560.85K(7.04M)845K11K
Net Income(39.41M)(41.03M)(43.27M)(45.31M)(88.61M)
Net Margin-317.4%-232.4%-170.5%-104.7%-15851.9%
EPS (Basic)(1.35)(3.78)(3.48)(2.37)(1.89)
EPS (Diluted)(1.35)(3.78)(3.48)(2.37)(1.89)
Weighted Avg Shares29.65M10.73M12.36M15.42M47.23M
Weighted Avg Shares (Diluted)29.65M10.73M12.36M15.42M47.23M

SLN Earnings Waterfall · TTM

NASDAQ:SLN · Revenue to Net Income

Key Ratios

EPS$-4.32
Gross Margin64.7%
Net Margin-15888.7%
P/E Ratio-3.0
P/S Ratio2462.0

Analysis

$921.5K of revenue converted into -$85.2M of net income for the selected period. Gross margin is 64.7% and net margin is -15888.7%, showing how much revenue survives after costs and taxes. EPS is $-4.32, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
10-QQuarterly reportNov 13, 2026
DEFA14ADEFA14A filingNov 12, 2026
8-KCurrent reportNov 12, 2026
SC 13G/ASC 13G/A filingNov 12, 2026
SC 13GSC 13G filingNov 5, 2026

How much revenue does SLN generate?

Silence Therapeutics plc (SLN) reported $559,000.00 of revenue in fiscal 2025.

Is SLN profitable?

Silence Therapeutics plc (SLN) reported -$88.61M of net income, with a net margin of -15851.9%.